Igene Biotechnology, Inc. (IGNE)
OTCMKTS · Delayed Price · Currency is USD
0.0000
0.00 (0.00%)
At close: Aug 21, 2025
Igene Biotechnology Statistics
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
IGNE has 1.56 billion shares outstanding.
| Current Share Class | 1.56B |
| Shares Outstanding | 1.56B |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.33 |
| PB Ratio | -0.00 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.15
| Current Ratio | 1.15 |
| Quick Ratio | 1.15 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.22 |
| Interest Coverage | -9.24 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -8.21% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -46.51% |
| Weighted Average Cost of Capital (WACC) | 13.20% |
| Revenue Per Employee | 267 |
| Profits Per Employee | -131,882 |
| Employee Count | 18 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | -32.98 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Relative Strength Index (RSI) | 40.02 |
| Average Volume (20 Days) | 112,551 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, IGNE had revenue of 4,804 and -2.37 million in losses. Loss per share was -0.00.
| Revenue | 4,804 |
| Gross Profit | 40,847 |
| Operating Income | -596,768 |
| Pretax Income | -2.37M |
| Net Income | -2.37M |
| EBITDA | -426,981 |
| EBIT | -596,768 |
| Loss Per Share | -0.00 |
Balance Sheet
The company has 269,290 in cash and 363,874 in debt, with a net cash position of -94,584 or -0.00 per share.
| Cash & Cash Equivalents | 269,290 |
| Total Debt | 363,874 |
| Net Cash | -94,584 |
| Net Cash Per Share | -0.00 |
| Equity (Book Value) | -4.44M |
| Book Value Per Share | -0.00 |
| Working Capital | 312,110 |
Cash Flow
In the last 12 months, operating cash flow was -1.68 million and capital expenditures 16,623, giving a free cash flow of -1.67 million.
| Operating Cash Flow | -1.68M |
| Capital Expenditures | 16,623 |
| Free Cash Flow | -1.67M |
| FCF Per Share | -0.00 |
Margins
| Gross Margin | 850.27% |
| Operating Margin | -12,422.31% |
| Pretax Margin | -49,414.72% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
IGNE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -24.87% |
| Shareholder Yield | -24.87% |
| Earnings Yield | -151,685.81% |
| FCF Yield | -106,413.93% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
IGNE has an Altman Z-Score of -21.9 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -21.9 |
| Piotroski F-Score | 2 |